Astrocytomas
Brain tumors that range from slow-growing to highly aggressive — now defined by molecular testing as much as by appearance under the microscope.
Quick Answer
Astrocytomas are brain tumors that develop from astrocytes, the star-shaped support cells of the brain. They can behave very differently depending on their grade and molecular characteristics. Today, diagnosis combines what the tumor looks like under the microscope with its molecular profile — especially IDH mutation status and other markers such as ATRX, TP53, and CDKN2A/B. This integrated diagnosis establishes the tumor type and grade and helps guide treatment, which may include surgery, active surveillance, radiation, chemotherapy, IDH-targeted therapy, or a clinical trial.
Key Takeaways
- Astrocytomas are gliomas that arise from astrocytes, the star-shaped support cells of the brain.
- They range from slower-growing grade 2 tumors to highly aggressive grade 4 tumors.
- Modern WHO classification defines astrocytoma using molecular features — particularly IDH mutation status, along with ATRX and TP53 — in addition to microscopic appearance.
- Certain molecular findings can determine grade; for example, homozygous deletion of CDKN2A/B establishes grade 4 in an IDH-mutant astrocytoma.
- “Anaplastic astrocytoma” is a retired term for a grade 3 tumor and may still appear on pathology reports issued before 2021.
- Maximal safe resection is often the first treatment when it can be performed safely.
- Treatment after surgery follows the integrated diagnosis and may include surveillance, radiation with chemotherapy, an IDH inhibitor such as vorasidenib, or a clinical trial.
At a Glance
| What it is | A glioma that arises from astrocytes, the brain’s star-shaped support cells |
|---|---|
| Behavior | Ranges from slow-growing (grade 2) to highly aggressive (grade 4) |
| Classification | WHO integrated diagnosis combining microscopic appearance with molecular profile |
| Defining molecular features | IDH1 or IDH2 mutation, typically with ATRX loss and TP53 mutation, and no 1p/19q co-deletion |
| Common symptoms | Seizures, headaches, weakness, speech or vision changes, or cognitive changes |
| Diagnosis | MRI with and without contrast, tissue diagnosis by a neuropathologist, and molecular testing including next-generation sequencing |
| Treatment | Maximal safe resection, followed by surveillance, radiation, chemotherapy, IDH-targeted therapy, or a clinical trial |
| Key molecular markers | IDH mutation status; also CDKN2A/B, MGMT promoter methylation, and 1p/19q |
Types and Grades of Astrocytoma
Astrocytomas are not a single type of brain tumor. They are a group of gliomas that can differ significantly in how they grow, how they respond to treatment, and their long-term outlook. Modern classification considers both how the tumor looks under a microscope and its molecular characteristics. Certain molecular findings can now determine grade on their own. One of the most important distinctions is IDH mutation status.
Adult Diffuse Astrocytoma, IDH-mutant
The most common astrocytoma in adults, typically diagnosed between the twenties and forties. These tumors carry a mutation in IDH1 or, less often, IDH2, and usually show loss of ATRX and mutation of TP53. They do not carry a 1p/19q co-deletion, which would instead indicate an oligodendroglioma.
Usually slower-growing and may be well tolerated for years.
Shows increased cell division and more aggressive behavior.
Assigned when specific aggressive features are present, including CDKN2A/B homozygous deletion.
Pediatric Circumscribed Astrocytic Gliomas
A separate group with sharper borders than diffuse astrocytomas, making complete removal — and in some cases cure — possible. Examples include pilocytic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma. Molecular findings such as BRAF alterations can sometimes open the door to targeted therapy.
Pediatric-Type Diffuse Gliomas
These tumors can resemble adult astrocytomas under the microscope but are biologically distinct and classified separately. They include diffuse midline glioma, H3 K27-altered; diffuse hemispheric glioma, H3 G34-mutant; and lower-grade pediatric gliomas defined by alterations such as BRAF or FGFR1.
Older terminology: “Anaplastic astrocytoma”
This is a retired term once used for grade 3 astrocytic tumors. Today, a tumor previously called anaplastic astrocytoma is classified according to its molecular profile. Patients diagnosed before 2021 may benefit from review or retesting of the original tissue because updated classification can affect prognosis and treatment recommendations.
Common Warning Signs
- New seizures
- Gradual headaches
- Subtle changes in thinking or personality
- Weakness, numbness, or speech difficulty
- Vision changes
When to Seek Care Promptly
- A first-time seizure
- Sudden severe headache
- Rapidly progressing weakness or speech difficulty
- New confusion or change in alertness
- Any rapidly worsening neurological symptom
Symptoms
Symptoms of an astrocytoma depend largely on the tumor’s location, size, and growth rate. Slower-growing tumors often produce symptoms gradually over months to years because the brain can adapt as the tumor expands; more aggressive tumors may cause symptoms that progress over weeks. A seizure is a common first symptom of a grade 2 IDH-mutant astrocytoma, while headache, nausea, and progressive weakness may reflect the tumor itself, surrounding swelling, or increased pressure within the skull.
Symptoms may include:
- Seizures
- Headaches, particularly new headaches that are worse in the morning
- Nausea or vomiting
- Progressive weakness, numbness, or clumsiness affecting one side of the body
- Speech or language difficulties
- Vision changes
- Problems with balance or coordination
- Changes in memory, thinking, behavior, or personality
Some slower-growing astrocytomas are discovered incidentally on imaging performed for another reason.
Diagnosis
Evaluation typically begins with a neurological examination and MRI of the brain with and without contrast. Beyond showing the tumor’s size and location, advanced MRI sequences can provide information that helps shape the working diagnosis before tissue is obtained. Perfusion imaging evaluates blood volume within the tumor, MR spectroscopy can detect metabolic patterns associated with IDH-mutant tumors, and diffusion tensor imaging maps nearby white-matter pathways. In some cases, a T2-FLAIR mismatch pattern on MRI can strongly suggest an IDH-mutant astrocytoma without 1p/19q co-deletion.
A definitive diagnosis generally requires tumor tissue obtained through surgical resection or biopsy. The tissue is examined by a neuropathologist and undergoes molecular testing to determine the tumor’s specific characteristics.
Why Molecular Testing Matters
Next-generation sequencing can detect IDH1 and IDH2 mutations and evaluate other important alterations, including CDKN2A/B, MGMT promoter methylation, TERT, EGFR, BRAF, and H3. In difficult cases, DNA methylation profiling may help classify a tumor that conventional testing leaves unresolved.
Modern astrocytoma classification combines microscopic appearance with molecular findings to create what pathologists call an integrated diagnosis. This layered report identifies the tumor’s histologic and molecular features and assigns a final CNS WHO grade. Molecular characterization is now a central part of the initial workup because these findings can change the diagnosis, expected course, and recommended treatment.
When a tumor is near areas responsible for movement, language, sensation, or vision, functional MRI and diffusion tensor tractography may be obtained before surgery. These studies can be incorporated into the intraoperative navigation system and, when needed, confirmed during surgery with direct electrical stimulation of the brain.
Treatment
Treatment for an astrocytoma depends on the tumor’s integrated diagnosis — including grade and molecular characteristics — as well as its location, growth, and the patient’s age and overall health.
Maximal Safe Surgery
When it can be performed safely, surgery is usually the first step. The goal is maximal safe resection: removing as much tumor as possible while protecting neurological function and obtaining enough tissue for complete molecular testing. More complete removal is associated with longer control of the disease, which is why surgery is planned around what can be removed safely rather than simply what can be reached.
For tumors in or near critical areas of the brain, Atlantic Brain and Spine uses a combination of advanced techniques selected for the individual tumor and patient.
Treatment After Surgery
What comes next depends on the integrated diagnosis. Some patients may be monitored with regular MRI scans, while others may need radiation therapy with chemotherapy, an IDH-targeted treatment such as vorasidenib, a clinical trial, or a combination of approaches.
One Diagnosis. Multiple Perspectives.
Every patient is reviewed at our multidisciplinary brain tumor board, bringing together neurosurgery, neuro-oncology, radiation oncology, neuropathology, and neuroradiology.
The team reviews the complete integrated diagnosis and develops a coordinated treatment plan. When an open clinical trial matches the tumor’s molecular profile, it can be considered alongside standard treatment options.
The Diagnosis-to-Treatment Pathway
1. Neurological evaluation
A neurological exam evaluates symptoms, strength, sensation, speech, vision, balance, and other functions.
2. Advanced MRI
MRI with and without contrast defines the tumor’s size and location; advanced imaging may help characterize the tumor and map nearby functional pathways.
3. Tissue diagnosis
Biopsy or surgical resection provides tissue for examination by a neuropathologist.
4. Molecular testing
IDH status and other markers, often evaluated with next-generation sequencing, establish the integrated diagnosis and CNS WHO grade.
5. Multidisciplinary review
The brain tumor team reviews the imaging, pathology, and molecular findings together and develops an individualized treatment strategy.
6. Treatment
Maximal safe surgery, surveillance, radiation, chemotherapy, IDH-targeted therapy, clinical trials, or a combination may be recommended.
7. Ongoing surveillance
Regular MRI and clinical follow-up monitor treatment response and watch for tumor progression or recurrence.
Frequently Asked Questions
An astrocytoma is a type of glioma that develops from astrocytic cells, which are support cells in the brain. Astrocytomas can vary significantly in how quickly they grow and behave. Today, they are classified using both tumor grade and molecular characteristics, which provide a more precise diagnosis and help guide treatment.
Some astrocytomas are slower-growing, while others are malignant and more aggressive. The tumor’s grade and molecular characteristics help determine its expected behavior. Because astrocytomas can grow into surrounding brain tissue, even slower-growing tumors require careful evaluation and ongoing monitoring.
Astrocytomas are classified according to their biological and molecular characteristics. IDH-mutant astrocytomas are classified as grade 2, 3, or 4, with higher grades generally associated with more aggressive behavior. Other tumors that were historically grouped with astrocytomas may now receive different diagnoses based on molecular testing.
Anaplastic astrocytoma is an older term historically used for a grade 3 astrocytic tumor. Under current classification, molecular testing—particularly IDH mutation status—is used to classify these tumors more precisely. Someone previously diagnosed with an anaplastic astrocytoma may therefore hear different terminology used today.
Both are types of glioma, but they have different biological and molecular characteristics. Glioblastoma is a highly aggressive glioma that is most commonly IDH-wildtype. Astrocytoma, IDH-mutant is a separate diagnosis that can be classified as grade 2, 3, or 4. Molecular testing helps distinguish between these tumors and guides treatment planning.
Diagnosis typically begins with a neurological examination and MRI of the brain with contrast. A definitive diagnosis generally requires tumor tissue obtained through surgery or biopsy. A neuropathologist examines the tissue and performs molecular testing, including IDH mutation status and other markers, to accurately classify the tumor and help guide treatment.
Treatment depends on the tumor’s diagnosis, grade, molecular characteristics, location, and the patient’s individual circumstances. Surgery is often the first treatment when the tumor can be safely removed. Depending on the specific tumor, additional treatment may include MRI surveillance, radiation therapy, chemotherapy, targeted therapy, clinical trials, or a combination of approaches.
IDH is an important molecular marker used to classify gliomas. An IDH mutation helps establish the tumor’s specific diagnosis and can provide information about how the tumor is likely to behave. IDH status is considered along with tumor grade and other molecular findings when determining prognosis and developing an individualized treatment plan.
These are much better suited to the new umbrella page than the existing FAQs, which are specifically framed around “low-grade gliomas,” including questions about whether those tumors are cancerous, why surgery is important, and whether radiation or chemotherapy will be needed.
Specialists Who Treat Astrocytomas and Low-Grade Gliomas
Your care is provided by Atlantic Brain and Spine's multidisciplinary brain tumor team, including fellowship-trained neurosurgeons.
Related Articles
View All Articles
An Unexpected Brain Tumor Diagnosis—and a Remarkable Recovery
After an unexpected meningioma diagnosis, Jim Van Arsdale turned to Yaron A. Moshel, MD, PhD, for brain tumor…
Still Running: How Brain Surgery Got a Glioblastoma Patient Back in the Race
At 77, Tom Brand was diagnosed with glioblastoma after losing his ability to speak. Following advanced brain surgery…
Brain Surgery Saved Her Life – Now She Saves Others as She Stands With Ukraine
After life-saving brain tumor surgery, Mariya Martynenko transformed her recovery into a mission—supporting Ukrainian refugees, veterans, and frontline…
It Takes a Team: How Collaborative Care Treated a Brain Tumor
When troubling symptoms turned out to be a brain tumor, Chris found expert, collaborative care at Atlantic Brain…
